SCHEMBL5720751

SCHEMBL5720751

CCNc1cc(C(=O)OC)cc(N(c2ccccc2)S(C)(=O)=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 1/20 0.46
BACE1 P56817 1/20 0.46
BACE2 Q9Y5Z0 1/20 0.46
POLB P06746 2/20 0.41
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
TSHR P16473 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
HIF1A Q16665 1/20 0.39
RAB9A P51151 3/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5928383 0.89 CTSD (0.48) CTSDBACE1BACE2POLBALDH1A1
SCHEMBL13229340 0.86 TSHR (0.49) POLBALDH1A1KDM4EKMT2AMEN1
SCHEMBL7864577 0.83 ACLY (0.44) POLBALDH1A1KDM4EKMT2AMEN1
SCHEMBL13229343 0.82 TSHR (0.45) CTSDBACE1BACE2POLBALDH1A1
SCHEMBL5928548 0.81 TSHR (0.44) CTSDBACE1BACE2POLBALDH1A1
SCHEMBL7857856 0.81 BACE1 (0.45) BACE1POLBALDH1A1KDM4EKMT2A
SCHEMBL5928542 0.81 CTSD (0.49) CTSDBACE1BACE2TSHRL3MBTL1
SCHEMBL5720749 0.80 KDM4E (0.43) CTSDBACE1BACE2POLBALDH1A1
SCHEMBL5928604 0.80 L3MBTL1 (0.38) CTSDBACE1BACE2POLBALDH1A1
SCHEMBL5720754 0.79 POLB (0.52) CTSDBACE1BACE2POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211740-A1 Novel compounds GLAXO GROUP LIMITED 2006-09-21 US disclosed
EP-1611089-A2 HYDROXYETHYLAMINE COMPOUNDS HAVING ASP2 INHIBITORY ACTIVITY FOR THE TREATMENT OF ALZHEIMER'S DISEASE GLAXO GROUP LIMITED (GB) 2006-01-04 EP disclosed
WO-2004080376-A2 HYDROXYETHYLAMINE COMPOUNDS HAVING ASP2 INHIBITORY ACTIVITY FOR THE TREATMENT OF ALZHEIMER’S DISEASE GLAXO GROUP LIMITED (GB) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211740-A1 Novel compounds BACE2, BACE1, PSEN2 CTSD 366/4885BACE1 2/4885BACE2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.